Condition
TED
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Active Not Recruiting1
Enrolling By Invitation1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05987423Phase 3Active Not Recruiting
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
NCT07182552Phase 1Enrolling By InvitationPrimary
Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants
NCT06769984Phase 1Not Yet RecruitingPrimary
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
Showing all 3 trials